title: The development of fulminant type 1 diabetes during chemotherapy for rectal cancer.
abstract: A 34-year-old man with a history of rectal cancer was receiving oral chemotherapy [tegafur-uracil (UFT) with leucovorin]. He visited our hospital due to nausea and abdominal pain, and his laboratory data revealed the presence of urinary ketones, hyperglycemia and high anion gap metabolic acidosis, and HbA1c level of 6.8%. Accordingly, we diagnosed fulminant type 1 diabetes. The development of fulminant type 1 diabetes during chemotherapy for malignancy is a rare, but potentially fatal condition. Therefore, clinicians should consider diabetic ketoacidosis in the differential diagnosis when examining chemotherapy patients who present with gastrointestinal symptoms.
authors.affiliation: Department of Diabetes and Endocrinology, Yokohama City Minato Red Cross Hospital; 2. Department of Internal Medicine, Ohkubo Hospital, Japan.
authors.forename: Junichiro
authors.initials: J
authors.lastname: Adachi
authors.forename: Makiyo
authors.initials: M
authors.lastname: Mimura
authors.forename: Naoki
authors.initials: N
authors.lastname: Gotyo
authors.forename: Takayuki
authors.initials: T
authors.lastname: Watanabe
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced*; D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D003937:Diagnosis, Differential; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced / Q000188:drug therapy; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D012004:Rectal Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D005641:Tegafur; D014498:Uracil; D002955:Leucovorin